Figure 6.

Inhibition of EGFR signaling in oral cancer pain. (A) Representative anti-EGFR immunoreactivity (Green) in TG sections (12 μm) from a mouse with retrograde labeling from the tongue (DiI, Red). DAPI was used to identify nuclei (Blue). More than 90% of all DiI-labeled neurons overlapped (Merge, Yellow) with EGFR immunoreactivity (×20 magnification). (B) Orofacial nociceptive behavior measured in mice 1 hour after HSC-3 supernatant injection into the tongue immediately followed by saline (Solid bar) or cetuximab treatment (Striped bar). Data were analyzed as a percent change from baseline gnawing behavior. Two-way ANOVA, **P < 0.01. ANOVA, analysis of variance; EGFR, epidermal growth factor receptor.